Know Cancer

or
forgot password

Phase IV, Non-interventional, Prospective, Open Label, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients


N/A
N/A
N/A
Open (Enrolling)
Male
Prostate Cancer

Thank you

Trial Information

Phase IV, Non-interventional, Prospective, Open Label, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients


Inclusion Criteria:



- Patients having been prescribed Depo-Eligard® 7.5 mg - 22.5 mg - 45 mg in accordance
with the terms of the marketing authorization.

Type of Study:

Observational

Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Evaluation of tolerability of treatment on a 4 point scale

Outcome Time Frame:

Last Visit (after at least 180 days of treatment)

Safety Issue:

No

Principal Investigator

Medical Director

Investigator Role:

Study Director

Investigator Affiliation:

Astellas Pharma Europe B.V.

Authority:

Belgium: Ethics Committee

Study ID:

BE-11-EGD-04

NCT ID:

NCT01793077

Start Date:

December 2011

Completion Date:

January 2015

Related Keywords:

  • Prostate Cancer
  • Prostate Cancer
  • Phase 4
  • Data collection
  • Observational
  • Depo-Eligard
  • Prospective
  • Non-interventional
  • Treatment
  • Prostatic Neoplasms

Name

Location